NCT06785415 2025-09-30Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple MyelomaMayo ClinicPhase 1/2 Recruiting37 enrolled
NCT05422027 2024-06-17Selinexor Plus VRd in High Risk Newly Diagnosed Multiple MyelomaSun Yat-sen UniversityPhase 1/2 Recruiting42 enrolled